TG Therapeutics Raised FY24 Briumvi U.S. Net Product Revenue Guidance to $290M-$300M From $270M-$290M
Portfolio Pulse from Benzinga Newsdesk
TG Therapeutics has raised its FY24 Briumvi U.S. net product revenue guidance to $290M-$300M from the previous $270M-$290M.
August 06, 2024 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TG Therapeutics has increased its FY24 Briumvi U.S. net product revenue guidance to $290M-$300M from $270M-$290M, indicating stronger than expected performance.
The increase in revenue guidance suggests that TG Therapeutics is experiencing stronger than expected demand for Briumvi, which is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100